Expanded conditional approval allows drugs that are undergoing their final clinical trial assessment and are supported by ...

Longevity seekers are taking rapamycin in hopes of living longer. Here's what a health and longevity doctor has to say about ...

Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and UseBiodexa plans to ...

A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway in the progression of diabetic nephropathy (DN) and explores its potential ...

Rapamycin is used to prevent graft rejection in transplant recipients based on its ability to suppress T-cell proliferation. The drug blocks the activity of a protein known as mammalian target of ...

Biodexa Pharmaceuticals (BDRX) announced that the U.S. Patent and Trademark Office allowed has U.S. patent application No. 17/391.495 titled ...

The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.

ISM001-055 was shown to have attenuated cellular senescence through the suppression of various aging processes, thus showing potential as a senomorphic drug.

Aubrey de Grey had a large mouse study of combinations of antiaging treatments. They did show that combination treatments did ...

An curved arrow pointing right. Could one pill help us live longer? Scientists and investors are racing to find a drug to slow aging, trying things like metformin and rapamycin. But the ...